In a recent webinar, industry experts explain how real-world data and patient-centric support can shape regulatory success ...

BeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin to treat NPC.

The FDA has issued more than 200 complete response letters, which detail reasons for non-approval of drug applications.

IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.

With clinical trials under pressure, industry leaders say it’s time for reform, digital transformation, and more patient-centric models.

The US dominates overall sales, yet GlobalData predicts that China is shaping up to be a formidable presence in the cell therapy space.

Achieving good oral bioavailability for targeted protein degraders (TPDs) is vital in providing a patient-friendly way to ...

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

Merck has entered a definitive agreement to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn.

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals ...

Zentiva Group has entered a licence and supply agreement with Lupin for the commercialisation of latter’s biosimilar Certolizumab Pegol.